Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
113.00    1.50 (1.35%)
Bid:
112.00
Ask:
114.00
Spread: 2.00 (1.786%)
Market Cap: £67.98m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

8 Apr 2010 07:00

RNS Number : 8639J
Intercede Group PLC
08 April 2010
 



8 April 2010

Intercede Group plc

("Intercede")

 

Trading Update for the Full Year to 31 March 2010

 

We are pleased to report that Intercede is continuing to experience growth in sales revenues, pre-exceptional operating profit and cash.

 

Revenues for the year ended 31 March 2010 are expected to be approximately 10% ahead of the previous year's reported revenues of £5.7m. This is a strong performance in a difficult economic market. However, with sales slightly below expectations and having maintained our planned investment for the growth of the business, the pre-exceptional operating profit for the year (2009: £1.9m) will be ahead of last year but lower than market expectations.

 

Cash balances at 31 March 2010 total £4.7m which compares to £3.7m at 31 March 2009.

 

As previously announced, the US and UK patent litigations involving ActivIdentity were settled on 23 March 2010. The exceptional charge to the current financial year for all of the legal fees and associated costs relating to this case is expected to be in the region of £1.5m. No further legal costs are expected to arise and, as previously advised, it is not anticipated that the patent license agreement included within the settlement will have a material impact on Intercede's current or future earnings.

 

Intercede Chairman and Chief Executive Richard Parris said:

 

 "I am pleased to report an improved trading performance against a backdrop of the increasing adoption of our technology by national governments, managed service providers and large enterprise customers. Our increasing market penetration has not only provided financial returns in the current period but is also creating annuity revenue streams for the future."

 

Intercede expects to announce its full year results for the year ended 31 March 2010 by mid June 2010.

 

About Intercede

 

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalisation, issuance and management.

 

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a program with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

 

For more information visit http://www.intercede.com

 

ENQUIRIES

Intercede Group plc

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

Tel. +44 (0)1455 558111

FinnCap

Clive Carver- Corporate Finance

Joanna Weaving - Corporate Broking

Tel. +44 (0)20 7600 1658

Pelham Bell Pottinger

Archie Berens / Francesca Tuckett

Tel. +44 (0)20 7337 1509

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSSWEFWFSSELL
Date   Source Headline
25th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSTransaction in Own Shares
19th Nov 20247:00 amRNSTransaction in Own Shares
18th Nov 20247:00 amRNSTransaction in Own Shares
15th Nov 20247:00 amRNSTransaction in Own Shares
14th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 20247:00 amRNSTransaction in Own Shares
12th Nov 20247:00 amRNSTransaction in Own Shares
11th Nov 20247:00 amRNSTransaction in Own Shares
8th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSNotice of Results & Investor Presentation
25th Oct 20247:00 amRNSShare Buyback Programme
11th Oct 20248:38 amRNSDirector/PDMR Shareholding
8th Oct 20247:00 amRNSTrading Update
1st Oct 20247:00 amRNSNotification of Trading Update and H1 FY25 Results
30th Sep 20247:00 amRNSContract Orders and Renewals
25th Sep 202412:51 pmRNSResult of AGM
20th Sep 202411:45 amRNSDirector/PDMR Shareholding
18th Sep 20247:00 amRNSContract Orders and Renewals
2nd Sep 20247:00 amRNSContract Orders and Subscription Renewals
30th Aug 20247:00 amRNSNotice of AGM and Publication of Annual Report
4th Jul 20243:58 pmRNSIssue of Equity & Total Voting Rights
28th Jun 20243:49 pmRNSIssue of Equity & Total Voting Rights
26th Jun 20247:00 amRNSPartnership with Carahsoft Technology Corp
19th Jun 20246:25 pmRNSHolding(s) in Company
18th Jun 20249:17 amRNSHolding(s) in Company
18th Jun 20247:15 amRNSDirector/PDMR Shareholding and Issue of Equity
18th Jun 20247:00 amRNSFinal Results
5th Jun 20247:00 amRNSNotice of Results & Investor Presentation
16th May 202412:00 pmRNSCapital Markets Day - Agenda Update
14th May 20246:17 pmRNSShare Incentive Scheme
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.